CZ281570B6 - Farmaceutický přípravek obsahující antagonistu receptoru angiotensinu-II a sloučeninu blokující vápníkové kanálky - Google Patents

Farmaceutický přípravek obsahující antagonistu receptoru angiotensinu-II a sloučeninu blokující vápníkové kanálky Download PDF

Info

Publication number
CZ281570B6
CZ281570B6 CS932351A CS235193A CZ281570B6 CZ 281570 B6 CZ281570 B6 CZ 281570B6 CS 932351 A CS932351 A CS 932351A CS 235193 A CS235193 A CS 235193A CZ 281570 B6 CZ281570 B6 CZ 281570B6
Authority
CZ
Czechia
Prior art keywords
tetrazol
biphenyl
imidazole
methyl
angiotensin
Prior art date
Application number
CS932351A
Other languages
Czech (cs)
English (en)
Inventor
Pancras Wong
Original Assignee
E.I. Du Pont De Nemours And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by E.I. Du Pont De Nemours And Company filed Critical E.I. Du Pont De Nemours And Company
Publication of CZ235193A3 publication Critical patent/CZ235193A3/cs
Publication of CZ281570B6 publication Critical patent/CZ281570B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CS932351A 1991-05-15 1992-05-14 Farmaceutický přípravek obsahující antagonistu receptoru angiotensinu-II a sloučeninu blokující vápníkové kanálky CZ281570B6 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70074091A 1991-05-15 1991-05-15
PCT/US1992/003873 WO1992020342A1 (en) 1991-05-15 1992-05-14 Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers

Publications (2)

Publication Number Publication Date
CZ235193A3 CZ235193A3 (en) 1994-03-16
CZ281570B6 true CZ281570B6 (cs) 1996-11-13

Family

ID=24814683

Family Applications (1)

Application Number Title Priority Date Filing Date
CS932351A CZ281570B6 (cs) 1991-05-15 1992-05-14 Farmaceutický přípravek obsahující antagonistu receptoru angiotensinu-II a sloučeninu blokující vápníkové kanálky

Country Status (11)

Country Link
EP (1) EP0584250A1 (ja)
JP (1) JP2930252B2 (ja)
AU (1) AU664375B2 (ja)
CA (1) CA2103276A1 (ja)
CZ (1) CZ281570B6 (ja)
IE (1) IE921534A1 (ja)
IL (1) IL101858A (ja)
MX (1) MX9202243A (ja)
NZ (1) NZ242724A (ja)
WO (1) WO1992020342A1 (ja)
ZA (1) ZA923557B (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3057471B2 (ja) 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
AU696868B2 (en) * 1994-03-29 1998-09-17 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles
JPH11500140A (ja) 1995-03-16 1999-01-06 ファイザー・インコーポレーテッド アムロジピン、アムロジピン塩、もしくはフェロジピンとａｃｅ阻害薬とを含有する組成物
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
SG142116A1 (en) 1998-07-10 2008-05-28 Novartis Ag Antihypersensitive combination of valsartan and calcium channel blocker
US7481803B2 (en) * 2000-11-28 2009-01-27 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
WO2001082858A2 (de) * 2000-05-04 2001-11-08 Ipf Pharmaceuticals Gmbh Neue verbindungen zur behandlung inflammatorischer und kardiovaskulärer erkrankungen
AU2002226365A1 (en) * 2000-12-01 2002-06-11 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
KR101194453B1 (ko) 2003-01-31 2012-10-24 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
TW200833325A (en) * 2006-12-26 2008-08-16 Daiichi Sankyo Co Ltd Pharmaceutical composition comprising ascorbic acid
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607004B1 (fr) * 1986-11-20 1990-06-01 Synthelabo Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
AU656551B2 (en) * 1990-12-14 1995-02-09 Smithkline Beecham Corporation Angiotensin II receptor blocking compositions

Also Published As

Publication number Publication date
ZA923557B (en) 1993-11-15
CZ235193A3 (en) 1994-03-16
NZ242724A (en) 1994-09-27
EP0584250A4 (ja) 1994-03-30
EP0584250A1 (en) 1994-03-02
JPH06508128A (ja) 1994-09-14
AU2026992A (en) 1992-12-30
IL101858A0 (en) 1992-12-30
WO1992020342A1 (en) 1992-11-26
CA2103276A1 (en) 1992-11-16
IE921534A1 (en) 1992-11-18
JP2930252B2 (ja) 1999-08-03
AU664375B2 (en) 1995-11-16
IL101858A (en) 1996-08-04
MX9202243A (es) 1992-11-01

Similar Documents

Publication Publication Date Title
CZ281570B6 (cs) Farmaceutický přípravek obsahující antagonistu receptoru angiotensinu-II a sloučeninu blokující vápníkové kanálky
EP0565634B1 (en) Angiotensin ii receptor blocking compositions
US6228874B1 (en) Pharmaceutical composition for angiotensin II-mediated diseases
EP0628313B1 (en) Combination of an angiotensin-II antagonising benzimidazole with manidipine for the treatment of hypertension
US5492904A (en) Composition of angiotensin-II receptor antagonists and calcium channel blockers
HU219404B (hu) Eljárás kardiális és vaszkuláris hipertrófia és/vagy hiperplazia kezelésére alkalmas angiotenzin-II-receptor blokkoló hatású vegyületet tartalmazó gyógyszerkészítmények előállítására
JPH11228410A (ja) イミダゾールアンジオテンシン−ｉｉ受容体拮抗薬からなる慢性腎不全治療剤
JP3057471B2 (ja) アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
DE69821252T2 (de) Verwendung eines Angiotensin-II Antagonisten zur Herstellung von Arzneistoffen zur Erhöhung der Überlebensrate von Nierentransplantationspatienten
JP2006517557A (ja) 脳卒中発作予防のための、アセチルサリチル酸およびアンジオテンシンｉｉ拮抗薬と組み合わせたジピリダモールの使用
SK78994A3 (en) Optic hypotensive agent and method of its preparation
WO2006028007A1 (ja) 糸球体疾患治療剤
JP2004523569A (ja) 抗高血圧薬とコレステロール吸収阻害薬の併用療法
EP2157089A1 (en) The therapeutic uses of imidazol-5-carboxylic acid derivatives
EP0612523B1 (en) Vascular hypertrophy suppressor
KR100222627B1 (ko) 앙기오텐신-ii 수용체 길항제 및 칼슘 채널 차단제의 신규한 조성물
JP2008133229A (ja) 医薬組成物

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20010514